Phase III Randomized Adjuvant Study of Chemotherapy in Node Positive Breast Cancer Patients -AC(Anthracycline-Cyclophosphamide) 4 cycles followed by Taxane 4 cycles (AC-Tac) versus Taxane 8 cycles and Paclitaxel versus Docetaxel-

INTERVENTION: ACP : Adriamycin 60mg/m2 or Epirubicin 75mg/m2 (30min. drip phleboclysis, day1) + Cyclophosphamide 600mg/m2 (60min. drip phleboclysis, day1) 4 cycles followed by Paclitaxel 175g/m2 (3 hours drip phleboclysis, day1) 4 cycles (1 cycle = 3 weeks, dosage on day1 of every cycle) ACD : Adriamycin 60mg/m2 or Epirubicin 75mg/m2 (30min. drip phleboclysis, day1) + Cyclophosphamide 600mg/m2 (60min. drip phleboclysis, day1) 4 cycles followed by Dosetaxel 75g/m2 (1 hour drip phleboclysis, day1) 4 cycles (1 cycle = 3 weeks, dosage on day1 of every cycle) PTX : Paclitaxel 175g/m2 (3 hours drip phleboclysis, day1) 8 cycles (1 cycle = 3 weeks, dosage on day1 of every cycle) DTX : Dosetaxel 75g/m2 (1 hour drip phleboclysis, day1) 8 cycles (1 cycle = 3 weeks, dosage on day1 of every cycle) CONDITION: node positive breast cancer PRIMARY OUTCOME: Disease‐Free Survival SECONDARY OUTCOME: Relapse‐Free Survival; Overall Survival; Health‐related QOL; Adverse Events; Efficacy of medical economy INCLUSION CRITERIA: (1)Histologically proven primary breast cancer (2)StageI,IIA,IIIB,IIIA (TNM staging system) (3)Proven node positive by node dissection or sentinel node biopsy (4)PS (Eastern Cooperative Oncology Group performance status scale) 0,1 (5)Relations to other treatments are (a)Treatment of this study started within 12 weeks after mastectomy/breast‐conserving surgery or node dissection, (b)No postoperative radiation, and (c)No endocrinotherapy, chemotherapy (6)WBC>=4,000 or neutrophilic leukocyte>=2,000, PLT>=100,000,T‐B=<1.5 , GPT(ALT)=<(every institution's reference value)*2.5, CRE<=1.5 (these values are tested within 2 weeks before registration for this study), no cardiac infraction or congestive heart failure, no grave ischemic heart disease or valvular disease (7)Written informed consent